Cytokinetics Q4 net loss $150M, cash $1.2B; aficamten PDUFA date Sept 26, 2025

CYTOKINETICS INC

2024-FY EPS reported -$5.26 revenue$18,474,000

Net loss Q4 2024 was $150.0M ($1.26/sh) vs $136.9M ($1.38/sh) in Q4 2023; FY net loss $589.5M.
Cash, cash equivalents and investments ~$1.2B at Dec 31, 2024, down ~$60M from Sept 30, 2024.
FDA accepted aficamten NDA with target PDUFA date of September 26, 2025; MAA validated in Europe.
Topline results from Phase 3 MAPLE-HCM trial expected in Q2 2025.
2025 GAAP operating expense guidance: $670M-$710M; non-cash stock comp $110M-$120M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.